Y-MABS THERAPEUTICS INC (YMAB)
US9842411095 - Common Stock
We assign a fundamental rating of 4 out of 10 to YMAB. YMAB was compared to 587 industry peers in the Biotechnology industry. YMAB has a great financial health rating, but its profitability evaluates not so good. YMAB is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
YMAB had negative earnings in the past year.
YMAB had a negative operating cash flow in the past year.
In the past 5 years YMAB always reported negative net income.
In the past 5 years YMAB always reported negative operating cash flow.
1.2 Ratios
YMAB has a better Return On Assets (-17.57%) than 84.79% of its industry peers.
With an excellent Return On Equity value of -21.84%, YMAB belongs to the best of the industry, outperforming 85.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.57% | ||
| ROE | -21.84% | ||
| ROIC | N/A |
ROA(3y)-36.76%
ROA(5y)-47.63%
ROE(3y)-46.48%
ROE(5y)-58.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 86.54%, YMAB belongs to the best of the industry, outperforming 90.60% of the companies in the same industry.
YMAB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.54% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
YMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for YMAB remains at a similar level compared to 1 year ago.
Compared to 5 years ago, YMAB has more shares outstanding
YMAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 8.53 indicates that YMAB is not in any danger for bankruptcy at the moment.
The Altman-Z score of YMAB (8.53) is better than 83.59% of its industry peers.
YMAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.53 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
A Current Ratio of 6.15 indicates that YMAB has no problem at all paying its short term obligations.
YMAB has a Current ratio of 6.15. This is in the better half of the industry: YMAB outperforms 62.22% of its industry peers.
YMAB has a Quick Ratio of 5.67. This indicates that YMAB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.67, YMAB is in line with its industry, outperforming 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.15 | ||
| Quick Ratio | 5.67 |
3. Growth
3.1 Past
YMAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.01%, which is quite impressive.
Looking at the last year, YMAB shows a quite strong growth in Revenue. The Revenue has grown by 12.60% in the last year.
Measured over the past years, YMAB shows a very strong growth in Revenue. The Revenue has been growing by 59.89% on average per year.
EPS 1Y (TTM)71.01%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q0%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y59.89%
Revenue growth 5YN/A
Revenue growth Q2Q-1.58%
3.2 Future
Based on estimates for the next years, YMAB will show a very negative growth in Earnings Per Share. The EPS will decrease by -24.12% on average per year.
The Revenue is expected to grow by 24.69% on average over the next years. This is a very strong growth
EPS Next Y3.66%
EPS Next 2Y13.65%
EPS Next 3Y-28.74%
EPS Next 5Y-24.12%
Revenue Next Year19.52%
Revenue Next 2Y19.05%
Revenue Next 3Y14.9%
Revenue Next 5Y24.69%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for YMAB. In the last year negative earnings were reported.
Also next year YMAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as YMAB's earnings are expected to decrease with -28.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.65%
EPS Next 3Y-28.74%
5. Dividend
5.1 Amount
No dividends for YMAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Y-MABS THERAPEUTICS INC
NASDAQ:YMAB (5/17/2024, 7:00:03 PM)
After market: 11.6 0 (0%)11.6
-0.25 (-2.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap507.85M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.57% | ||
| ROE | -21.84% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.54% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.15 | ||
| Quick Ratio | 5.67 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)71.01%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y3.66%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)12.6%
Revenue growth 3Y59.89%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y